Obicetrapib not checked
NewAmsterdam Pharma · 10 mg tablet · TA-8995
FollowEvery change as it happens, and a Monday email
Trials
7 active
19 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks”In the company’s words, NCT06496243 on ClinicalTrials.gov
- Tested for
- Lipidemia (2 trials), Atherosclerotic Cardiovascular Disease, Mixed Dyslipidemia, Hypercholesterolaemia, Coronary Artery Disease, Plaque, Atherosclerotic, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS) and 3 more
- Main trialPhase 3
- “This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.”In the company’s words, NCT05202509 on ClinicalTrials.gov
- Other names
- tablets · FDC · 10 mg tablet · CETP inhibitor · Repatha · TA-8995
Other drugs for Atherosclerotic Cardiovascular Disease
- LaroprovstatAstraZeneca · Phase 3
- TemsirolimusMercator MedSystems, Inc. · Phase 3
- PelacarsenNovartis Pharmaceuticals · Phase 3
- OlpasiranAmgen · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- OrforglipronEli Lilly · Phase 3
Coming up6
- NovPhase 3 trial completes · ClinicalTrials.gov
- NovPhase 2 trial completes · ClinicalTrials.gov
- Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 daysTrials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2026 | Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | |
| Phase 3Recruiting | Jan 2027 | Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days | |
| Phase 3Active, not recruiting | Nov 2027 | A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | |
| Phase 3Active, not recruiting | Mar 2028 | A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | |
| Phase 2Recruiting | Sep 2026 | Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers | |
| Phase 2Recruiting | Nov 2026 | Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | |
| Phase 2Recruiting | Sep 2028 | Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease | |
| Phase 3Completed | 28 May 2024 | Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. | |
| Phase 3Completed | 26 Sep 2024 | Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies | |
| Phase 2Completed | 7 May 2021 | Randomized Study of Obicetrapib in Combination With Ezetimibe | |
| Phase 2Completed | 24 May 2021 | Randomized Study of Obicetrapib as an Adjunct to Statin Therapy | |
| Phase 2Completed | 12 Aug 2022 | Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | |
| Phase 2Completed | 24 Mar 2023 | A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. | |
| Phase 2Completed | 9 May 2023 | Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease | |
| Phase 1Completed | 2 Dec 2023 | A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin | |
| Phase 1Completed | 12 Mar 2024 | PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function | |
| Phase 1Completed | 25 Apr 2024 | Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib | |
| Phase 1Unknown | 26 Sep 2024 | Investigating the Effect of Obicetrapib on Lipoprotein Metabolism | |
| Phase 1Completed | 12 Nov 2024 | A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026